Concise and Scalable Total Syntheses of Lamellarin Z and other Natural Lamellarins: Regiocontrolled Assembly of the Central Pyrrole Core and Cross Dehydrogenative Coupling Enroute to the Pentacyclic Coumarin-Pyrrole-Isoquinoline Scaffold

Virendra Kumar, Abdus Salam, Dileep Kumar and Tabrez Khan

29 Jul 2020

Full Research Paper

SI total synthesis VK.pdf; 5.9 MB

Tabrez Khan - https://orcid.org/0000-0002-9875-3101
Concise and Scalable Total Syntheses of Lamellarin Z and other Natural Lamellrarins: Regiocontrolled Assembly of the Central Pyrrole Core and Cross Dehydrogenative Coupling Enroute to the Pentacyclic Coumarin-Pyrrole-Isoquinoline Scaffold

Virendra Kumar, Abdus Salam, Dileep Kumar and Tabrez Khan*

Address: Organic Synthesis Laboratory, School of Basic Sciences, Indian Institute of Technology Bhubaneswar, Odisha 752050, India.

Email: Tabrez Khan – tabrez@iitbbs.ac.in

Abstract

An efficient construction of the central 1,2,4-trisubstituted pyrrole core via one-pot [3+2] cycloaddition/elimination/aromatization sequence-based domino process and subsequent Pd-mediated cross dehydrogenative coupling between the C-H bonds of pyrrole and the peripheral aryl rings enables rapid access to the pentacyclic coumarin-pyrrole-isoquinoline scaffolds which were smoothly elaborated to the targeted lamellarins alkaloids. The total synthesis of lamellarins Z and S with the highest overall yield reported till date, besides the synthesis of several other natural lamellinarins have been realized in 5-6 steps with overall yields ranging from 20-27%.
Keywords

aziridine; cross-dehydrogenative coupling; domino process; lamellarins; total synthesis

Introduction

Lamellarins constitute one of the most attractive marine pyrrole alkaloids which have engaged the attention of synthetic organic and medicinal chemists for more than past two decades [1, 2] and continue to do so [3]. The underlying fact behind the world-wide attention enjoyed by these secondary metabolites is their interesting structural architecture comprising of a highly oxygenated pentacyclic coumarin-pyrrole-isoquinoline scaffold, typically in the type I and type II lamellarins (Figure 1) [4]. Also, the type III lamellarins with a relatively simple non-fused 3,4-diarylated pyrrole core with diverse oxygenation patterns on the aryl rings have been considered attractive targets for total synthesis [5]. Besides striking structural attributes, lamellarins have also equally fascinated the chemists with their interesting bioactivity profile including antitumor activity, multi-drug resistant (MDR) reversal activity in cancer cells, HIV integrase inhibitor activity, antibacterial and antioxidant activity among others [1,4a, 6]. Several reviews pertaining to the synthetic contributions from various groups and SAR development in the context of lamellarins are testimony to the enormous popularity enjoyed by these marine pyrrole alkaloids [1,2,4a,6].
From the total synthesis perspective, most of the approaches reported towards lamellarins could be segregated into two categories. The first category of modular approaches originating from a commercially available pyrrole core involves functionalization of the heterocyclic core enroute to the natural alkaloid; while the second category involves the construction of the functionalized central pyrrole core enroute to the natural product [1b,2a]. Though, most of the second category approaches emanate from isoquinoline derivatives, recently some innovative approaches involving the construction of the pre-functionalized pyrrole core have surfaced in the literature [3a,7]. One such approach was recently reported by us [8], which discloses a novel one-pot domino process involving [3+2] cycloaddition of unactivated aziridine with β-bromo-β-nitrostyrene which interestingly affords 1,2,4-trisubstituted pyrrole core in a highly regioselective manner instead of the expected 1,2,3-trisubstituted pyrrole core (Scheme 1) [8,9]. Also, subsequent elaboration of the 1,2,4-trisubstituted pyrrole core to several natural and unnatural lamellarins was then demonstrated in an elegant manner with reasonably good overall yield [10].
Scheme 1: One-step domino process for the synthesis of functionalized central pyrrole core.

Our continuing interest in marine pyrrole alkaloids (MPAs) [8,10] gave us the realization that despite numerous synthetic efforts towards various members of the lamellarin family, there still exist some members for which either no chemical synthesis subsists or there are very few reports. This prompted us to further validate the generality and flexibility of our already reported synthetic strategy towards lamellarins by demonstrating its applicability for the total synthesis of lamellarins Z [11,12], G, and S besides other frequently targeted biologically significant lamellarins L, N and D. In this article, we present the details of our synthetic investigation in the context of these natural marine pyrrole alkaloids (MPAs).

Results and Discussion

A concise retrosynthetic strategy as depicted in Scheme 2 and similar to the one explored by us earlier [10] to access the targeted type I and type II lamellarins was
adopted in order to facilitate the rapid acquisition of the pentacyclic coumarin-pyrrole-isoquinoline scaffold. Annulation of aziridine-2-carboxylate (1) with substituted β-bromo-β-nitrostyrene (2) as per our reported condition [8] was planned to arrive at the pyrrole-2-carboxylate (3). Swapping of the alkyl ester in 3 with appropriately substituted phenyl esters through a straightforward 2-step synthetic manoeuvre was the next planned task to access the key intermediate (4). Then, a crucial one-pot Pd-mediated cross dehydrogenative coupling (CDC) reaction between sp² C-H bonds of central pyrrole core and peripheral aryl rings was conceptualized to arrive at the pentacyclic type I lamellarin scaffold [10,13], from which the type II lamellarin scaffold could also be accessed through a dehydrogenation reaction.

Scheme 2: Retrosynthetic Strategy towards Type I and Type II lamellarins.

Toward the operationalization of the devised retrosynthetic plan outlined in Scheme 2, initially, we choose to target lamellarins S and Z. In this context, the N-substituted aziridine-2-carboxylate (5) was subjected to annulation with β-bromo-β-nitrostyrene (6a) as depicted in Scheme 3 under our reported optimized condition [8] to arrive exclusively at the pyrrole-2-carboxylate (7) in good yield. The ethyl ester (7) was then elaborated to the phenyl esters (10a,b) through a 2-step synthetic manoeuvre
involving hydrolysis followed by EDC.HCl mediated coupling of the resultant pyrrole-2-carboxylic acid (8) with phenol 9a,b [14,15]. After having access to 10a,b we then executed the key Pd-mediated CDC reaction in presence of Cu(OAc)$_2$ as cooxidant to establish two C-C bonds in a consecutive manner between the central pyrrole core and the appended phenyl rings in the ester functionality as well as the phenyl ring of phenethyl substitution on the pyrrole-N-atom, to arrive at the pentacyclic lactones (11a,b) in moderate yields [10,13]. Subsequently, exhaustive deisopropylation of the isopropyl ethers present on the aryl rings using BCl$_3$ smoothly delivered the target MPAs, lamellarin S and lamellarin Z in excellent yields. The NMR spectral data of the synthetic lamellarins S and Z were found to be in decent agreement with the data reported for the natural products [16,17].

\[ \text{Scheme 3: Total synthesis of lamellarin S and lamellarin Z.} \]

Next, our attention turned towards the synthesis of lamellarins G, L, and N. As highlighted in Scheme 4, a similar reaction sequence as described above was adopted for the other lamellarins. The pyrrole ester (12) accessed from the annulation of the aziridine-2-carboxylate 5 with β-bromo-β-nitrostyrene (6b), was subjected to
saponification and subsequently, a coupling of the resultant acid (13) with 9b,c [15,18] to arrive at the phenyl tethered esters (14a,b) in excellent yields. Next, the crucial Pd-mediated CDC reaction in presence of Cu(OAc)₂ as cooxidant was executed on 14a,b, to arrive at the pentacyclic lactones (15a,b) in moderate yields [10,13]. Lastly, BCl₃ mediated selective deprotection of the isopropyl ethers present on the aryl rings efficiently furnished lamellarin G and lamellarin L in 88% yields. On the other hand, the subjection of the pentacyclic lactone (15b) first to a DDQ mediated oxidation of the fused dihydroisoquinoline ring, followed by BCl₃ mediated selective deprotection of the isopropyl ethers present on the aryl rings in 16, effortlessly delivered lamellarin N. Also, the NMR spectral data for the synthetic lamellarins G, L and N were in close agreement with the reported data [19, 20].

Scheme 4: Total synthesis of lamellarin G, L and N.

In our present synthetic endeavour, the final target left was lamellarin D and the substitution pattern present in it dictated for a forward synthesis as captured in Scheme 5. Employing the same aziridine-2-carboxylate (5) as used previously (vide supra), but
a different β-bromo-β-nitrostyrene in the form of 6c, the formation of pyrrole ester (17) was facilitated under the optimized condition [8,10]. The pyrrole ester (17) was then elaborated to the phenyl tethered pyrrole-2-carboxylate (19) through a 2 step synthetic protocol via pyrrole-2-carboxylic acid (18). Then, subjection of 19 to the Pd-mediated CDC reaction condition enabled the consecutive C-C bond formation to deliver the pentacyclic isoquinoline-coumarin fused pyrrole 20 [10,13]. With 20 in hand, repetition of a similar sequence of reaction as used for accessing lamellarin N involving DDQ mediated dehydrogenation and BCl₃ facilitated deprotection of the isopropyl ethers, effortlessly furnished the targeted lamellarin D in good yield. Also, the NMR spectral data for the synthetic lamellarin D were in close agreement with the reported data [7b].

Scheme 5: Total synthesis of lamellarin D.

Conclusion

In conclusion, we have successfully demonstrated the adaptation of our recently disclosed one-pot domino process for the construction of the 1,2,4-trisubstituted central pyrrole core with diverse oxygenation pattern on the aryl rings. Also, a further
extension to the pentacyclic lamellarin scaffolds has been demonstrated through a one-pot CDC reaction, thereby enabling a 5-step total synthesis of lamellarins Z and S with the highest overall yields of 27% and 26% respectively, reported till date in the literature.\textsuperscript{12,21} Further, the 5-step synthesis of lamellarins G and L accomplished with an overall yield of 26% each, compares reasonably well, either in terms of step economy or overall yield with many of the earlier reported synthesis. Even the 6-step synthesis of lamellarins N and D accomplished with overall yields of 24% and 20% respectively compares satisfactorily with the previous synthetic reports.

**Experimental**

**General Information:** All the reagents were purchased from commercial suppliers and used without further purification. While most of the desired solvents supplied by commercial suppliers were dried using the standard drying procedures.\textsuperscript{22} All the moisture and air sensitive reactions were performed under a flow of nitrogen or argon atmosphere using flame-dried or oven-dried glassware with magnetic stirring. All purifications were done using column chromatography with 100-200 mesh size SiO\textsubscript{2}-gel as the stationary phase. Distilled EtOAc and petroleum ether were typically used for column chromatography. The \textsuperscript{1}H & \textsuperscript{13}C\{}\textsuperscript{1}H\} NMR spectra were recorded on 400 MHz Bruker spectrometer using CDCl\textsubscript{3} (H: \(\delta = 7.26\) and C: \(\delta = 77.0\) ppm) or TMS (\(\delta = 0.0\)) residual solvent peaks as internal standard and DMSO-d\textsubscript{6} ((H: \(\delta = 2.50\) and C: \(\delta = 39.52\pm0.06\) ppm). The following abbreviations are used for spin multiplicity: s = singlet, d = doublet, t = triplet, q = quartet, p = quintet/pentet, sept. = septet, dd = doublet of doublet, ddd = doublet of doublet of doublet, td = triplet of doublet, dq = doublet of quartet and m = multiplet. The chemical shifts are reported as \(\delta\) values (ppm) and the coupling constants (\(J\) values are reported in Hz. High Resolution Mass
Spectra (HRMS) were obtained using electron spray ionization (ESI) technique and TOF mass analyzer. IR spectra were recorded on a Bruker FT/IR-460 Plus spectrometer. Melting points were determined on a Buchi M-560 apparatus and are uncorrected. Progress of the reactions were monitored using precoated SiO$_2$-gel GF254 TLC plates while spot visualizations were done under UV light and using spot developing stains like $p$-anisaldehyde, ceric ammonium molybdate, ninhydrin or KMnO$_4$.

**Ethyl 1-(3-isopropoxy-4-methoxyphenethyl) aziridine-2-carboxylate (5):** As per our reported protocol, in an oven-dried round-bottom flask under N$_2$ atmosphere, ethyl 2,3-dibromopropanoate (1.3 g, 5.0 mmol) was dissolved in EtOH (5 mL). After the solution was stirred at 0 °C for 10 min, 3-isopropoxy-4-methoxyphenethylamine (3.04 g, 15.0 mmol, 3 equiv.) dissolved in ~2 mL of ethanol was added dropwise to the flask over 10 min. The reaction was then allowed to warm to rt and continued stirring for another 6 h, until complete consumption of starting material was indicated by the TLC analysis. Upon reaction completion, the solvent was removed under reduced pressure, and the resultant residue was subjected to purification using SiO$_2$-gel column chromatography to arrive at the desired aziridine-2-carboxylate, 5 as a pale yellow oil (1.23 g, 80% yield); $R_f$ = 0.8 (50% EtOAc + pet. ether). IR (neat): $\nu_{\text{max}}$ 1746, 1644, 1606, 1513, 1454, 1416, 1384, 1262, 1234, 1186, 1110, 1029, 985 cm$^{-1}$; $^1$H NMR (400 MHz, CDCl$_3$): $\delta$ 6.78 (d, $J =$ 8 Hz, 1H), 6.74 (d, $J =$ 1.6 Hz, 1H), 6.72 (dd, $J_1 =$ 1.6 Hz, $J_2 =$ 8 Hz, 1H), 4.49 (sept, $J =$ 6 Hz, 1H), 4.24-4.10 (m, 2H), 3.82 (s, 3H), 2.90-2.79 (m, 2H), 2.54 (t, $J =$ 7.2 Hz, 2H), 2.12 (dd, $J_1 =$ 1.2 Hz, $J_2 =$ 3.2 Hz, 1H), 1.95 (dd, $J_1 =$ 3.2 Hz, $J_2 =$ 6.4 Hz, 1H), 1.50 (dd, $J_1 =$ 1.2 Hz, $J_2 =$ 6.4 Hz, 1H), 1.34 (d, $J =$ 6 Hz, 6H), 1.26 (t, $J =$ 7.2 Hz, 3H); $^{13}$C NMR (100 MHz, CDCl$_3$): $\delta$ 170.9, 149.0, 147.2, 132.0, 121.2, 116.9, 112.2, 71.5, 62.6, 61.1, 56.0, 37.6, 35.6, 34.4, 22.2, 22.1, 14.2. HRMS (ESI) m/z calcd for C$_{17}$H$_{26}$NO$_4$ (M+H)$^+$: 308.1856; found: 308.1841.
1) **General procedure for the preparation of β-bromo-β-nitrostyrene:** To a cold solution of β-nitrostyrene (2.5 mmol, 1 equiv.) in DCM at 0 °C, pyridine (0.4 mL, 5 mmol, 2 equiv.) was added followed by pyridinium tribromide (0.8 g, 2.5 mmol, 1 equiv.) in two portions. The reaction was then allowed to warm to rt over the next 3-12 h until complete consumption of starting material. Upon reaction completion, water was added followed by extraction with DCM. Drying of the organic phase over Na₂SO₄ followed by removal of the solvent under reduced pressure gave a crude residue which was purified by column chromatography to access β-bromo-β-nitrostyrene.

(Z)-4-(2-bromo-2-nitrovinyl)-1,2-diisopropoxybenzene (6a): Following general procedure 1, using (E)-1,2-diisopropoxy-4-(2-nitrovinyl)benzene (0.66 g, 2.5 mmol), 6a was obtained as yellow solid (0.61 g, 71% yield); Rᵣ = 0.8; (15% EtOAc + pet. ether); mp 78-80 °C. IR (neat): νₓₓₓ 1590, 1503, 1300, 1267, 1174, 1138, 1106, 1010, 997 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 8.6 (s, 1H), 7.64 (d, J = 2 Hz, 1H), 7.49 (dd, J₁ = 2 Hz, J₂ = 8.8 Hz, 1H), 6.96 (d, J = 8.4 Hz, 1H), 4.63 (sept, J = 6 Hz, 1H), 4.48 (sept, J = 6 Hz, 1H), 1.39 (d, J = 6 Hz, 6H), 1.36 (d, J = 6 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃): δ 153.2, 148.4, 136.6, 127.4, 125.2, 122.5, 120.1, 115.4, 115.4, 72.9, 71.7, 22.1 (2C), 22.0 (2C). HRMS (ESI) m/z calcd for C₁₄H₁₉BrNO₄ (M+H)⁺: 344.0492; found: 344.0484.

(Z)-4-(2-bromo-2-nitrovinyl)-2-isopropoxy-1-methoxybenzene (6b): Following general procedure 1, using (E)-2-isopropoxy-1-methoxy-4-(2-nitrovinyl) benzene (0.59 g, 2.5 mmol), 6b was obtained as a yellow solid (0.76 g, 97% yield); Rᵣ = 0.7; (20% EtOAc + pet. ether); mp 95-96 °C. IR (neat): νₓₓₓ 1642, 1586, 1527, 1510, 1302, 1263, 1140, 1017, 963, 931 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.62 (s, 1H), 7.63 (d, J = 2 Hz, 1H), 7.49 (dd, J₁ = 2 Hz, J₂ = 8.4 Hz, 1H), 6.96 (d, J = 8.4 Hz, 1H), 4.58 (sept, J = 6 Hz, 1H), 3.94 (s, 3H), 1.41 (d, J = 6 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃): δ 153.9, 147.2, 136.7, 127.1, 125.2, 122.4, 116.8, 111.6, 71.8, 56.1, 21.9 (2C). HRMS (ESI) m/z calcd for C₁₂H₁₅BrNO₄ (M+H)⁺: 316.0179; found: 316.0173.
(Z)-4-(2-bromo-2-nitrovinyl)-1-isopropoxy-2-methoxybenzene (6c): Following general procedure 1 using (E)-1-isopropoxy-2-methoxy-4-(2-nitrovinyl)benzene (0.59 g, 2.5 mmol), 21b was obtained as yellow solid (0.66 g, 83% yield); R_t = 0.7; (20% EtOAc + pet. ether); mp 73-75°C. IR (neat): ν_max 1586, 1529, 1468, 1303, 1268, 1144, 1106, 1031, 945 cm⁻¹;¹H NMR (400 MHz, CDCl₃): δ 8.63 (s, 1H), 7.60 (d, J = 2 Hz, 1H), 7.49 (dd, J₁ = 2.4 Hz, J₂ = 8.4 Hz, 1H), 6.96 (d, J = 8.8 Hz, 1H), 4.68 (sept, J = 6 Hz, 1H), 3.92 (s, 3H), 1.43 (d, J = 6 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃): δ 151.3, 149.8, 136.7, 126.9, 125.0, 122.2, 113.6, 113.5, 71.3, 56.1, 21.9 (2C). HRMS (ESI) m/z calcd for C₁₂H₁₅BrNO₄ (M+H)⁺ : 316.0179; found: 316.0171.

Gram Scale Synthesis of Ethyl 4-(3,4-diisopropoxyphenyl)-1-(3-isopropoxy-4-methoxypheneth-yl)-1H-pyrrole-2-carboxylate (7): As per our reported procedure, in an oven-dried seal tube, under nitrogen atmosphere, 6a [(Z)-4-(2-bromo-2-nitrovinyl)-1,2-diisopropoxybenzene] (1 g, 2.9 mmol, 1 equiv.) was taken. After that 5 [ethyl 1-(3-isopropoxy-4-methoxyphenethyl)aziridine-2-carboxylate] (0.89 g, 2.9 mmol, 1 equiv.) dissolved in toluene (2 mL) was added. The reaction was then sealed while maintaining the N₂ atmosphere and then stirred in a preheated oil bath at 150°C for 6 h, until complete consumption of starting materials was indicated upon reaction monitoring. After reaction completion, the solvent was removed under reduced pressure and the crude residue was subjected to purification using SiO₂-gel flash column chromatography to access 7 as pale yellow oil (1.3 g, 85% yield); R_t = 0.3; (10% EtOAc + pet. ether). IR (neat): ν_max 1638, 1514, 1505, 1470, 1454, 1384, 1371, 1261, 1245, 1136, 1092, 1024, 988 cm⁻¹;¹H NMR (400 MHz, CDCl₃) δ 7.15 (d, J = 2 Hz, 1H), 6.98 (d, J = 2 Hz, 1H), 6.95 (dd, J₁ = 2.4 Hz, J₂ = 8.4 Hz, 1H), 6.86 (d, J = 8.4 Hz, 1H), 6.79 (d, J = 2.0 Hz, 1H), 6.78 (d, J = 8.4 Hz, 1H), 6.69 (dd, J₁ = 2 Hz, J₂ = 8.2 Hz, 1H), 6.59 (d, J = 2.0 Hz, 1H), 4.54-4.37 (m, 5H), 4.32 (q, J = 7.2 Hz, 2H), 3.81 (s, 3H), 2.98 (t, J = 7.2 Hz, 2H), 1.39 (t, J = 7.2 Hz, 3H), 1.34 (d, J = 6 Hz, 6H), 1.33 (d, J
13C NMR (100 MHz, CDCl₃): δ 161.1, 149.3, 149.2, 147.8, 147.2, 131.0, 128.7, 125.3, 123.7, 122.1, 121.5, 118.8, 118.6, 116.9, 115.7, 115.1, 112.1, 72.4, 72.3, 71.6, 59.9, 56.0, 51.2, 37.7, 22.33 (2C), 22.28 (2C), 22.1 (2C), 14.5. HRMS (ESI) m/z calcd for C₃₁H₄₂NO₆ (M+H)+: 524.3007; found: 524.3002.

4-(3,4-diisopropoxyphenyl)-1-(3-isopropoxy-4-methoxyphenethyl)-1H-pyrrole-2-carboxylic acid (8): To a solution of 7 (0.9 g, 1.7 mmol, 1 equiv.) in ethanol : water (3:1, 25 mL), crushed NaOH pellets (0.34 g, 8.5 mmol, 5 equiv.) were added at rt and the reaction was then allowed to reflux for 5 h, until completion of the saponification process was indicated by TLC analysis. The reaction was worked up by removing the volatiles under reduced pressure and the resultant residue was neutralized with 1N HCl. The aqueous phase was subjected to extraction with EtOAc (4 × 30 mL). Drying of the organic phase over Na₂SO₄ and then removal of solvent under reduced pressure gave a crude residue which was subjected to SiO₂-gel column chromatography to access pure acid 8 as a white solid (0.79 g, 92% yield); Rᵣ = 0.5 (30% EtOAc + pet. ether); mp 96-97 °C. IR (neat): νmax 1660, 1565, 1548, 1479, 1463, 1402, 1380, 1264, 1235, 1184, 1141, 1113, 1028, 994 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.32 (d, J = 2 Hz, 1H), 6.99 (d, J = 2 Hz, 1H), 6.96 (dd, J₁ = 2 Hz, J₂ = 8 Hz, 1H), 6.89 (d, J = 8.4 Hz, 1H), 6.87 (d, J = 2 Hz, 1H), 6.80 (d, J = 8 Hz, 1H), 6.70 (dd, J₁ = 1.6 Hz, J₂ = 8.4 Hz, 1H), 6.65 (d, J = 2 Hz, 1H), 4.54-4.43 (m, 5H), 3.82 (s, 3H), 3.02 (t, J = 7.2 Hz, 2H), 1.36 (d, J = 6 Hz, 6H), 1.34 (d, J = 6 Hz, 6H), 1.31 (d, J = 6 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃): δ 165.8, 149.4, 149.2, 147.9, 147.3, 130.8, 128.2, 126.8, 124.2, 121.3, 121.0, 118.8, 118.6, 117.2, 116.7, 115.6, 112.1, 72.4, 72.3, 71.5, 56.0, 51.6, 37.7, 22.32 (2C), 22.28 (2C), 22.1 (2C). HRMS (ESI) m/z calcd for C₂₉H₃₈NO₆ (M+H)+: 496.2694; found: 496.2687.

2) General procedure for the pyrrole-2-carboxylic acid-phenol coupling: To a solution of pyrrole-2-carboxylic acid (1 equiv.) and phenol (1 equiv.) in dichloromethane (5
mL/mmol), EDC.HCl (1.1 equiv.) and DMAP (1.1 equiv.) were added sequentially at rt and the reaction was allowed to stir at rt for 12 h until complete consumption of starting materials was indicated by TLC analysis. The reaction was worked up by removing the solvent under reduced pressure and subjection of the resultant residue to SiO₂-gel flash column chromatography to access the phenyl tethered pyrrole-2-carboxylates.

**3,4-diisopropoxyphenyl 4-((3,4-diisopropoxyphenyl)-1-(3-isopropoxy-4-methoxyphenethyl)-1H-pyrrole-2-carboxylate (10a):** Following the general procedure 2, using 8 (0.3 g, 0.6 mmol, 1 equiv.) and 9a [3,4-diisopropoxyphenol] (0.13 g, 0.6 mmol, 1 equiv.), 10a was obtained as a pale yellow oil (0.38 g, 91% yield); \( R_f = 0.6 \) (20% EtOAc + pet. ether). IR (neat): \( \nu_{\text{max}} \) 1714, 1605, 1561, 1505, 1472, 1384, 1261, 1109, 1044, 988 cm⁻¹; \(^1\)H NMR (400 MHz, CDCl₃) 7.37 (d, \( J = 2 \) Hz, 1H), 7.02 (d, \( J = 2 \) Hz, 1H), 6.98 (dd, \( J_1 = 2.4 \) Hz, \( J_2 = 8.4 \) Hz, 1H), 6.95 (d, \( J = 8.8 \) Hz, 1H), 6.90-6.88 (m, 2H), 6.79-6.77 (m, 2H), 6.74 (dd, \( J_1 = 2.4 \) Hz, \( J_2 = 8.8 \) Hz, 1H), 6.69 (dd, \( J_1 = 1.6 \) Hz, \( J_2 = 8.4 \) Hz, 1H), 6.60 (d, \( J = 2 \) Hz, 1H), 4.55-4.48 (m, 3H), 4.46-4.36 (m, 4H), 3.81 (s, 3H), 3.01 (t, \( J = 7.2 \) Hz, 2H), 1.37-1.33 (m, 24H), 1.26 (d, \( J = 6 \) Hz, 6H); \(^{13}\)C NMR (100 MHz, CDCl₃): \( \delta \) 159.5, 149.9, 149.4, 149.2, 147.9, 147.2, 146.5, 145.0, 130.7, 128.3, 126.5, 124.2, 121.6, 121.1, 119.2, 118.8, 118.6, 116.8, 116.4, 115.7, 114.1, 112.0, 111.2, 73.1, 72.4 (2C), 72.0, 71.5, 56.0, 51.4, 37.7, 22.34 (2C), 22.31 (2C), 22.30 (2C), 22.2 (2C), 22.1 (2C). HRMS (ESI) m/z calcd for C₄₁H₅₄NO₈ (M+H)⁺: 688.3844; found: 688.3822.

**4-isopropoxy-3-methoxyphenyl 4-((3,4-diisopropoxyphenyl)-1-(3-isopropoxy-4-methoxyphenethyl)-1H-pyrrole-2-carboxylate (10b):** Following the general procedure 2, using 8 (0.45 g, 0.9 mmol, 1 equiv.) and 9b [4-isopropoxy-3-methoxyphenol] (0.16 g, 0.9 mmol, 1 equiv.), 10b was obtained as a pale yellow oil (0.58 g, 97% yield); \( R_f = 0.7 \) (30% EtOAc + pet. ether). IR (neat): \( \nu_{\text{max}} \) 1717, 1559, 1542, 1508, 1265, 1223, 1187, 1136, 1109, 1066, 1047, 989 cm⁻¹; \(^1\)H NMR (400 MHz, CDCl₃)
7.38 (d, J = 2 Hz, 1H), 7.02 (d, J = 2 Hz, 1H), 6.99 (dd, J1 = 2 Hz, J2 = 8.4 Hz, 1H), 6.93 (d, J = 8.4 Hz, 1H), 6.91-6.88 (m, 2H), 6.78-6.72 (m, 3H), 6.68 (dd, J1 = 2 Hz, J2 = 8.2 Hz, 1H), 6.60 (d, J = 2 Hz, 1H), 4.55-4.44 (m, 5H), 4.42-4.36 (m, 1H), 3.87 (s, 3H), 3.81 (s, 3H), 3.01 (t, J = 7.2 Hz, 2H), 1.38 (d, J = 6 Hz, 6H), 1.36 (d, J = 6 Hz, 6H), 1.40 (d, J = 6 Hz, 6H), 1.26 (d, J = 6 Hz, 6H); 13C NMR (100 MHz, CDCl3): δ 159.6, 151.1, 149.4, 149.2, 147.9, 147.2, 145.0, 144.6, 130.7, 128.3, 126.5, 124.3, 121.6, 121.1, 118.8, 118.6, 117.0, 116.5, 116.4, 115.7, 113.4, 112.1, 106.6, 72.4 (2C), 72.2, 71.6, 56.04, 56.0, 51.3, 37.7, 22.33 (2C), 22.29 (2C), 22.2 (2C), 22.1 (2C). HRMS (ESI) m/z calcd for C39H50NO8 (M+H)+: 660.3531; found: 660.3520.

3) General procedure for the cross-dehydrogenative coupling (CDC) reaction: Using the earlier reported procedure,10,13 an oven-dried schlenk tube was charged with phenyl esters (1 equiv.), Pd(OAc)2 (2 equiv.) and Cu(OAc)2 (6 equiv.) under N2 atmosphere. Then, dimethylacetamide (3 mL/mmol) followed by K2CO3 (2 equiv.) was added maintaining the inert atmosphere and the reaction was allowed to stir at 95 °C for 28-36 h. Upon reaction completion indication by TLC analysis, the reaction was filtered through celite and the celite bed was washed with EtOAc. The filtrates were combined and subjected to solvent removal under reduced pressure to arrive at a crude residue which was purified by SiO2-gel flash column chromatography to access pentacyclic coumarin fused pyrrolo-dihydroisoquinolines.

14-(3,4-diisopropoxyphenyl)-2,3,11-triisopropoxy-12-methoxy-8,9-dihydro-6H-chromeno[4′,3′:4,5]pyrrolo[2,1-a]isoquinolin-6-one (11a): Following the general CDC reaction procedure 3, using 10a (0.25 g, 0.36 mmol), 11a was obtained as a white solid (0.102 g, 41% yield); Rf = 0.8 (EtOAc). IR (neat): νmax 1712, 1649, 1643, 1572, 1536, 1513, 1484, 1416, 1268, 1207, 1109, 1035, 936 cm⁻¹; 1H NMR (400 MHz, CDCl3) δ 7.10 (d, J = 8.8 Hz, 1H), 7.02-7.00 (m, 2H), 6.92 (s, 1H), 6.76 (s, 1H), 6.72 (s, 1H), 6.71 (s, 1H), 4.87-4.80 (m, 1H), 4.76-4.69 (m, 1H), 4.59-4.40 (m, 4H), 4.00-3.94 (m,
1H), 3.34 (s, 3H), 3.10-3.06 (m, 2H), 1.40-1.28 (m, 24H), 1.14 (d, J = 6 Hz, 6H); 13C NMR (100 MHz, CDCl3) δ 155.7, 150.2, 148.8, 148.7, 148.6, 147.3, 146.4, 145.2, 136.0, 129.2, 128.2, 126.4, 123.8, 120.3, 119.5, 119.4, 115.0, 114.7, 113.6, 111.1, 110.8, 109.2, 105.4, 72.8, 72.2, 72.16, 71.9, 71.4, 55.1, 42.5, 28.7, 22.25, 22.23, 22.20, 22.07 (3C), 22.0 (2C), 22.9 (2C). HRMS (ESI) m/z calcd for C41H50NO8 (M+H)+ : 684.3531; found: 684.3559.

14-(3,4-diisopropoxyphenyl)-2,11-diisopropoxy-3,12-dimethoxy-8,9-dihydro-6H-chromeno[4',3':4,5]pyrrolo[2,1-a]isoquinolin-6-one (11b): Following the general oxidative coupling procedure 6, using 10b (0.338 g, 0.5 mmol, 1 equiv.), 11b was obtained as a white solid (0.141 g, 42% yield); RF = 0.4 (20% EtOAc + pet. ether). IR (neat): νmax 1715, 1648, 1541, 1508, 1488, 1456, 1418, 1338, 1269, 1209, 1162, 1110, 1031, 938 cm⁻¹; 1H NMR (400 MHz, CDCl3) δ 7.10 (d, J = 8.4 Hz, 1H), 7.04-7.02 (m, 2H), 6.89 (s, 1H), 6.76 (s, 1H), 6.71 (d, J = 2.8 Hz, 2H), 4.87-4.81 (m, 1H), 4.75-4.68 (m, 1H), 4.57-4.48 (m, 2H), 4.47-4.41 (m, 1H), 4.00-3.94 (m, 1H), 3.85 (s, 3H), 3.34 (s, 3H), 3.10-3.06 (m, 2H), 1.40 (d, J = 6 Hz, 3H), 1.39 (d, J = 6 Hz, 3H), 1.37 (d, J = 6 Hz, 6H), 1.30 (d, J = 6 Hz, 3H), 1.29 (d, J = 6 Hz, 3H), 1.16 (d, J = 6 Hz, 6H); 13C NMR (100 MHz, CDCl3) δ 155.7, 150.2, 149.9, 148.73, 148.66, 147.3, 146.1, 143.6, 136.0, 129.2, 128.2, 126.4, 123.8, 120.3, 119.5, 119.4, 114.9, 114.7, 113.6, 110.4, 109.2, 108.2, 100.8, 72.8, 71.9, 71.4, 71.1, 56.1, 55.1, 42.5, 28.7, 22.26, 22.24, 22.20, 22.07 (2C), 22.04, 21.76, 21.74. HRMS (ESI) m/z calcd for C39H46NO8 (M+H)+ : 656.3218; found: 656.3206.

4) General procedure for the BCl3 mediated deisopropylation: To a cold solution of pentacyclic isopropylated phenyl ether (1 equiv.) in DCM (3 mL/0.1 mmol of the substrate) at -78°C, BCl3 (1M solution in DCM, 10 equiv.) was added dropwise over 5 min. and after stirring at the same temperature for almost 20 min., the reaction was allowed to warm to rt and stirred for another 3 h until the formation of a prominent new
spot was indicated by TLC analysis. The reaction was worked up by quenching it with MeOH followed by removal of the volatiles under reduced pressure. To the resultant residue, H₂O was added and extracted with EtOAc. Drying of the organic phase over Na₂SO₄ and then removal of the solvent under reduced pressure gave a crude residue that was subjected to SiO₂-gel flash column to access the deisopropylated compounds.

**Lamellarin S**: Exhaustive deisopropylation on 11a (0.025 g, 0.036 mmol) using general procedure 4, afforded lamellarin S as a white solid (0.016 mg, 92% yield); Rᵣ = 0.3 (80% EtOAc + pet. ether) with NMR spectral data similar to those reported in the literature.¹⁶ IR (neat): νmax 2928, 2855, 1677, 1278, 1196, 1049, 955 cm⁻¹;¹H NMR (400 MHz, CD₃OD) δ 6.98 (d, J = 8 Hz, 1H), 6.87 (d, J = 2 Hz, 1H), 6.83 (s, 1H), 6.77 (dd, J₁ = 1.6 Hz, J₂ = 8 Hz, 1H), 6.75 (s, 1H), 6.70 (s, 1H), 6.62 (s, 1H), 4.70-4.54 (m, 2H), 3.38 (s, 3H), 3.00 (t, J = 6.8 Hz, 2H);¹³C NMR (100 MHz, MeOD-d₄) δ 157.6, 148.1, 147.46, 147.41, 147.3, 146.73, 146.7, 143.4, 138.6, 129.9, 128.7, 128.1, 123.7, 120.2, 119.0, 117.5, 116.4, 115.8, 113.8, 111.3, 110.4, 109.8, 104.2, 55.6, 43.5, 29.3.

**Lamellarin Z**: Exhaustive deisopropylation on 11b (0.025 g, 0.01 mmol) using general procedure 4, afforded lamellarin Z as a white solid (0.016 g, 89% yield); Rᵣ = 0.6 (80% EtOAc + pet. ether) which was spectroscopically found to be in good agreement with the earlier reported data.¹⁷ IR (neat): νmax 2889, 2839, 1654, 1560, 1542, 1523, 1458, 1377, 1363, 1340, 1276, 1205, 1188, 1161, 1117, 1080, 1042, 1026, 964 cm⁻¹;¹H NMR (400 MHz, DMSO-d₆) δ 9.34 (s, 1H), 9.12 (s, 1H), 9.08 (s, 1H), 8.92 (s, 1H), 7.00 (s, 1H), 6.93 (d, J = 8 Hz, 1H), 6.76 (d, J = 2 Hz, 1H), 6.72 (s, 1H), 6.70 (s, 1H), 6.69 (dd, J₁ = 8 Hz, J₂ = 2 Hz, 1H), 6.55 (s, 1H), 4.71-4.65 (m, 1H), 4.55-4.49 (m, 1H), 3.80 (s, 3H), 3.29 (s, 3H), 3.01-2.97 (m, 2H);¹³C NMR (100 MHz, DMSO-d₆) δ 154.3, 147.8, 146.9, 146.1, 145.9, 145.3, 144.6, 142.8, 136.0, 127.1, 126.9, 125.4, 121.5, 118.1, 117.7, 116.6, 115.2, 114.7, 112.5, 110.2, 109.3, 108.4, 100.7, 55.8, 54.6, 41.9, 27.5. HRMS (ESI) m/z calcd for C₂₇H₂₁NO₈ (M+H)⁺: 488.1340; found: 488.1333.
Ethyl 1-((3-isopropoxy-4-methoxyphenethyl)-4-(3-isopropoxy-4-methoxyphenyl)-1H-pyrrole-2-carboxylate (12): As per the procedure described for synthesis of pyrrole-2-carboxylate 7, using 5 [ethyl 1-((3-isopropoxy-4-methoxyphenethyl)aziridine-2-carboxylate] (0.68 g, 2.2 mmol, 1 equiv.) and 6b [(Z)-4-(2-bromo-2-nitrovinyl)-2-isopropoxy-1-methoxybenzene] (0.7 g, 2.2 mmol, 1 equiv.) with a reaction time of 5 h, 12 was obtained after flash column chromatography as pale yellow oil (0.91 g, 83% yield); Rf = 0.6; (20% EtOAc + pet. ether). IR (neat): νmax 1716, 1698, 1556, 1538, 1519, 1505, 1454, 1433, 1417, 1395, 1372, 1360, 1337, 1249, 1137, 1092 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.15 (d, J = 2 Hz, 1H), 6.97-6.95 (m, 2H), 6.83 (d, J = 8.4 Hz, 1H), 6.79-6.77 (m, 2H), 6.69 (dd, J₁ = 2 Hz, J₂ = 8 Hz, 1H), 6.60 (d, J = 2 Hz, 1H), 4.56 (sept, J = 6.0 Hz, 1H), 4.49 (t, J = 6.8 Hz, 2H), 4.41 (sept, J = 6.0 Hz, 1H), 4.32 (q, J = 7.2 Hz, 2H), 3.84 (s, 3H), 3.81 (s, 3H), 2.98 (t, J = 6.8 Hz, 2H), 1.39 (t, J = 7.2 Hz, 3H), 1.37 (d, J = 6 Hz, 6H), 1.27 (d, J = 6 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃): δ 161.1, 149.2 (2C), 147.4, 147.2, 131.0, 127.6, 125.3, 123.7, 122.1, 121.5, 118.0, 116.9, 115.1, 113.7, 112.4, 112.0, 71.6, 71.5, 60.0, 56.1, 56.0, 51.3, 37.7, 22.2 (2C), 22.1 (2C), 14.5. HRMS (ESI) m/z calcd for C₂₉H₃₈NO₆ (M+H)+ : 496.2694; found: 496.2689.

1-(3-isopropoxy-4-methoxyphenethyl)-4-(3-isopropoxy-4-methoxyphenyl)-1H-pyrrole-2-carboxylic acid (13): Applying the saponification procedure described for accessing acid 8, hydrolysis of 12 (0.37 g, 0.75 mmol, 1 equiv.) in EtOH : H₂O (3:1, 15 mL) using crushed NaOH pellets (0.15 g, 3.75 mmol, 5 equiv.) with reaction time of 5 h, afforded the pure acid 13 was obtained as a white solid (0.317 g, 91% yield); Rf = 0.6 (40% EtOAc + pet. ether); mp 124-126 °C. IR (neat): νmax 1649, 1555, 1519, 1460, 1433, 1396, 1372, 1337, 1252, 1232, 1188, 1137, 1108, 1064, 1026, 991 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.32 (d, J = 2 Hz, 1H), 6.98-6.96 (m, 2H), 6.87-6.85 (m, 2H), 6.80 (d, J = 8 Hz, 1H), 6.70 (dd, J₁ = 1.6 Hz, J₂ = 8.2 Hz, 1H), 6.66 (d, J = 2 Hz, 1H), 4.59-
4.43 (m, 4H), 3.86 (s, 3H), 3.83 (s, 3H), 3.03 (t, J = 7.2 Hz, 2H), 1.39 (d, J = 6 Hz, 6H), 1.31 (d, J = 6 Hz, 6H); $^{13}$C NMR (100 MHz, CDCl$_3$): δ 165.7, 149.3, 149.2, 147.5, 147.3, 130.8, 127.3, 126.8, 124.3, 121.3, 120.9, 118.0, 117.2, 116.6, 113.6, 112.4, 112.1, 71.6, 71.4, 56.1, 56.0, 51.6, 37.8, 22.2 (2C), 22.1 (2C). HRMS (ESI) m/z calcd for C$_{27}$H$_{34}$NO$_6$ (M+H)$^+$ : 468.2381; found: 468.2376.

4-isopropoxy-3-methoxyphenyl 1-(3-isopropoxy-4-methoxyphenethyl)-4-(3-isopropoxy-4-methoxyphenyl)-1H-pyrrole-2-carboxylate (14a): Following the general procedure 2, using acid 13 (0.29 g, 0.62 mmol, 1 equiv.) and 9b [4-isopropoxy-3-methoxyphenol] (0.114 g, 0.62 mmol, 1 equiv.), 14a was obtained as a pale yellow oil (0.337 g, 86% yield); $R_f$ = 0.4 (20% EtOAc + pet. ether). IR (neat): $\nu_{\text{max}}$ 1717, 1603, 1509, 1467, 1445, 1419, 1384, 1261, 1224, 1187, 1138, 1110, 1068, 1048, 803 cm$^{-1}$; $^1$H NMR (400 MHz, CDCl$_3$) 7.38 (d, J = 1.6 Hz, 1H), 7.02-6.99 (m, 2H), 6.93 (d, J = 8.8 Hz, 1H), 6.91 (d, J = 1.6 Hz, 1H), 6.86 (d, J = 8.8 Hz, 1H), 6.79-6.73 (m, 3H), 6.69 (dd, J$_1$ = 2 Hz, J$_2$ = 8.2 Hz, 1H), 6.61 (d, J = 2 Hz, 1H), 4.60-4.46 (m, 4H), 4.45-4.36 (m, 1H), 3.87 (s, 3H), 3.86 (s, 3H), 3.80 (s, 3H), 3.02 (t, J = 7.2 Hz, 2H), 1.39 (d, J = 6 Hz, 6H), 1.38 (d, J = 6 Hz, 6H), 1.27 (d, J = 6.4 Hz, 6H); $^{13}$C NMR (100 MHz, CDCl$_3$): δ 159.6, 151.1, 149.3, 149.2, 147.4, 147.2, 145.0, 144.6, 130.7, 127.3, 126.4, 124.3, 121.6, 121.1, 118.1, 116.9, 116.4, 116.3, 113.6, 113.4, 112.4, 112.0, 106.6, 72.1, 71.6, 71.5, 56.1, 56.0, 55.98, 51.3, 37.7, 22.19 (2C), 22.16 (2C), 22.1 (2C). HRMS (ESI) m/z calcd for C$_{37}$H$_{46}$NO$_8$ (M+H)$^+$ : 632.3218; found: 632.3211.

3-isopropoxy-4-methoxyphenyl 1-(3-isopropoxy-4-methoxyphenethyl)-4-(3-isopropoxy-4-methoxyphenyl)-1H-pyrrole-2-carboxylate (14b): Following the general procedure 2, using acid 13 (0.54 g, 1.156 mmol, 1 equiv.) and 9c [3-isopropoxy-4-methoxyphenol] (0.21 g, 1.156 mmol, 1 equiv.), 14b was obtained as a pale yellow oil (0.68 g, 93% yield); $R_f$ = 0.7 (20% EtOAc + pet. ether). IR (neat): $\nu_{\text{max}}$ 1717, 1604, 1509, 1465, 1386, 1225, 1185, 1110, 1068, 1048, 1030, 990 cm$^{-1}$; $^1$H
NMR (400 MHz, CDCl₃) 7.38 (d, J = 2 Hz, 1H), 7.02-6.99 (m, 2H), 6.91-6.89 (m, 2H), 6.86 (d, J = 8.8 Hz, 1H), 6.79-6.75 (m, 3H), 6.69 (dd, J₁ = 2 Hz, J₂ = 8 Hz, 1H), 6.62 (d, J = 2 Hz, 1H), 4.61-4.50 (m, 4H), 4.43-4.37 (m, 1H), 3.88 (s, 3H), 3.87 (s, 3H), 3.81 (s, 3H), 3.01 (t, J = 7.2 Hz, 2H), 1.40 (d, J = 6 Hz, 6H), 1.27 (d, J = 6 Hz, 6H); ¹³C NMR (100 MHz, CDCl₃): δ 159.6, 149.3, 149.2, 148.0, 147.8, 147.4, 147.2, 144.1, 130.7, 127.3, 126.4, 124.3, 121.6, 121.1, 118.0, 116.9, 116.3, 113.7, 113.6, 112.4, 112.0 (2C), 109.7, 71.6, 71.5 (2C), 56.4, 56.1, 56.0, 51.4, 37.7, 22.2 (2C), 22.1 (2C), 22.0 (2C). HRMS (ESI) m/z calcd for C₃₇H₄₆NO₈ (M+H)⁺: 632.3218; found: 632.3214.

**2,11-diisopropoxy-14-(3-isopropoxy-4-methoxyphenyl)-3,12-dimethoxy-8,9-dihydro-6H-chromeno[4',3':4,5]pyrrolo[2,1-a]isoquinolin-6-one (15a):** Following the general CDC reaction procedure 3, using 14a (0.182 g, 0.28 mmol), 15a was obtained as a white solid (0.071 g, 39% yield); Rᵋ = 0.5 (30% EtOAc + pet. ether). IR (neat): νmax 2981, 2897, 1704, 1618, 1483, 1453, 1418, 1268, 1240, 1209, 1162, 1111, 1030 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.08-7.03 (m, 3H), 6.90 (s, 1H), 6.76 (s, 1H), 6.73 (s, 1H), 6.65 (s, 1H), 4.86-4.79 (m, 1H), 4.78-4.71 (m, 1H), 4.58-4.47 (m, 2H), 3.98-3.94 (m, 1H), 3.93 (s, 3H), 3.86 (s, 3H), 3.34 (s, 3H), 3.09 (t, J = 6.8 Hz, 2H), 1.38 (d, J = 6 Hz, 3H), 1.37 (d, J = 6 Hz, 3H), 1.34 (d, J = 6 Hz, 3H), 1.32 (d, J = 6 Hz, 3H), 1.17 (d, J = 6 Hz, 3H), 1.16 (d, J = 6 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 155.7, 150.0, 149.8, 148.7, 148.2, 147.3, 146.1, 143.7, 136.0, 128.4, 128.1, 126.4, 123.4, 120.2, 117.4, 114.8, 114.7, 113.6, 112.7, 110.3, 109.1, 107.9, 100.8, 71.4, 71.2 (2C), 56.3, 56.1, 55.1, 42.5, 28.7, 22.1 (2C), 22.0, 21.9, 21.83, 21.79. HRMS (ESI) m/z calcd for C₃₇H₄₂NO₈ (M+H)⁺: 628.2905; found: 628.2892.

**3,11-diisopropoxy-14-(4-isopropoxy-3-methoxyphenyl)-2,12-dimethoxy-8,9-dihydro-6H-chromeno[4',3':4,5]pyrrolo[2,1-a]isoquinolin-6-one (15b):** Following the general CDC reaction procedure 3, using 14b (0.47 g, 0.75 mmol), 15b was
obtained as a white solid (0.19 g, 40% yield); \( R_f = 0.4 \) (30% EtOAc + pet. ether). IR (neat): \( \nu_{\text{max}} \) 2930, 1700, 1485, 1419, 1281, 1270, 1253, 1192, 1121, 1030, 1015, 930 cm\(^{-1}\); \(^1\)H NMR (400 MHz, CDCl\(_3\)) \( \delta \) 7.10-7.03 (m, 3H), 6.92 (s, 1H), 6.77 (s, 1H), 6.72 (s, 1H), 6.66 (s, 1H), 4.85-4.72 (m, 2H), 4.63-4.50 (m, 3H), 3.92 (s, 3H), 3.43 (s, 3H), 3.34 (s, 3H), 3.10 (t, \( J = 6.4 \) Hz, 2H), 1.41-1.36 (m, 18H); \(^{13}\)C NMR (100 MHz, CDCl\(_3\)) \( \delta \) 155.7, 150.0, 148.6, 148.0, 147.3, 147.0, 146.5, 146.0, 136.0, 128.3, 127.9, 126.3, 123.6, 120.2, 117.8, 114.8, 114.6, 113.6, 112.6, 110.4, 109.1, 104.8, 103.4, 71.36, 71.34, 71.25, 56.3, 55.5, 55.1, 42.4, 28.6, 22.0 (2C), 22.0, 21.9, 21.8 (2C).

HRMS (ESI) m/z calcd for C\(_{37}\)H\(_{42}\)NO\(_8\) (M+H\(^+\)) : 628.2905; found: 628.2894.

**Lamellarin G**: Deisopropylation on 15a (0.020 g, 0.03 mmol) using general procedure 4, afforded lamellarin G as a white solid (0.014 g, 88% yield); \( R_f = 0.6 \) (70% EtOAc + pet. ether) which was spectroscopically found to be in good agreement with the earlier reported data.\(^1\)\(^9\) IR (neat): \( \nu_{\text{max}} \) 2977, 2931, 1637, 1561, 1542, 1509, 1458, 1439, 1420, 1383, 1260, 1187, 1137, 1109, 1067, 1048, 1032, 988 cm\(^{-1}\); \(^1\)H NMR (400 MHz, DMSO-d\(_6\)) \( \delta \) 9.43 (br s, 1H), 9.30, (s, 1H), 8.99 (s, 1H), 7.13 (d, \( J = 8 \) Hz, 1H), 7.00 (s, 1H), 6.83 (dd, \( J_1 = 8.0 \) Hz, \( J_2 = 2.0 \) Hz 1H), 6.81 (d, \( J = 2 \) Hz, 1H), 6.72 (s, 1H), 6.66 (s, 1H), 6.48 (s, 1H), 4.69-4.63 (m, 1H), 4.57-4.51 (m, 1H), 3.85 (s, 3H), 3.80 (s, 3H), 3.25 (s, 3H), 2.98 (t, \( J = 6.8 \) Hz, 2H); \(^{13}\)C NMR (100 MHz, DMSO-d\(_6\)) \( \delta \) 154.4, 147.9, 147.7, 147.5, 147.0, 146.0, 144.7, 142.8, 136.1, 127.2 (2C), 126.9, 121.5, 118.0, 117.6, 115.3, 114.4, 113.3, 112.6, 110.1, 109.2, 108.3, 100.8, 55.9, 55.8, 54.6, 42.0, 27.6.

**Lamellarin L**: Deisopropylation on 15b (0.030 g, 0.04 mmol) using general procedure 4, afforded lamellarin L as a white solid (0.020 g, 83% yield); \( R_f = 0.4 \) (70% EtOAc + pet. ether) which was spectroscopically found to be in good agreement with the earlier reported data.\(^2\)\(^0\) IR (neat): \( \nu_{\text{max}} \) 1685, 1582, 1481, 1431, 1276, 1242, 1231, 1167, 1048 cm\(^{-1}\); \(^1\)H NMR (400 MHz, DMSO-d\(_6\)) \( \delta \) 9.78 (s, 1H), 9.53 (s, 1H), 9.40 (s, 1H), 9.40 (s, 1H), 7.15 (d, \( J = 8.0 \) Hz, 1H), 6.90-6.87 (m, 2H), 6.79 (s, 1H), 6.74 (s, 1H), 6.67 (s, 1H), 6.65 (s,
1H), 4.65-4.58 (m, 1H), 4.56-4.50 (m, 1H), 3.81 (s, 3H), 3.36 (s, 3H), 3.27 (s, 3H), 2.99 (t, J = 6.8 Hz, 2H); \textsuperscript{13}C NMR (100 MHz, DMSO-d\textsubscript{6}) \(\delta\) 154.5, 147.8, 147.7, 147.3, 147.0, 146.2, 145.8, 144.7, 136.0, 127.7, 127.5, 127.4, 121.9, 118.2, 118.0, 115.5, 114.2, 113.6, 112.5, 109.4, 108.9, 105.2, 103.8, 56.2, 55.5, 55.1, 21.9 (2C), 21.85 (2C), 21.79 (2C). HRMS (ESI) m/z calcd for C\textsubscript{28}H\textsubscript{24}NO\textsubscript{8} (M+H\textsuperscript{+}) : 502.1496; found: 502.1489.

**3,11-diisopropoxy-14-(4-isopropoxy-3-methoxyphenyl)-2,12-dimethoxy-6H-chromeno[4',3':4,5]pyrrolo[2,1-a]isoquinolin-6-one (16):** To the solution of pentacyclic coumarin fused pyrrolo-dihydroisoquinolines 15b (0.020 g, 0.03 mmol, 1 equiv.) in DCM (1 mL), DDQ (0.017 g, 0.075 mmol, 2.5 equiv.) was added at rt. The reaction was then allowed to stir at room temperature for 12 h until complete consumption of starting material was indicated by TLC analysis. Subjection of the crude reaction mixture to SiO\textsubscript{2}-gel flash column chromatography afforded 16 as a white solid (0.019 g, 96% yield); \(R_f\) = 0.5 (30% EtOAc + pet. ether). IR (neat): \(\nu_{\text{max}}\) 2924, 1693, 1519, 1480, 1434, 1286, 1229, 1180, 1110, 1039, 945, 859 cm\textsuperscript{-1}; \(\textsuperscript{1}H\) NMR (400 MHz, CDCl\textsubscript{3}) \(\delta\) 9.22 (d, \(J = 7.2\) Hz, 1H), 7.19 (dd, \(J_1 = 2\) Hz, \(J_2 = 8\) Hz, 1H), 7.17 (s, 1H), 7.15 (d, \(J = 8\) Hz, 1H), 7.13 (d, \(J = 2\) Hz, 1H), 7.10 (s, 1H), 7.03 (d, \(J = 7.2\) Hz, 1H), 6.96 (s, 1H), 6.75 (s, 1H), 4.74-4.67 (m, 1H), 4.63-4.50 (m, 2H), 3.96 (s, 3H), 3.45 (s, 3H), 3.44 (s, 3H), 1.43 (d, \(J = 6\) Hz, 6H), 1.40 (d, \(J = 6\) Hz, 6H), 1.35 (d, \(J = 6\) Hz, 3H), 1.34 (d, \(J = 6\) Hz, 3H); \textsuperscript{13}C NMR (100 MHz, CDCl\textsubscript{3}) \(\delta\) 155.7, 150.2, 148.5, 148.1, 147.9, 146.6, 146.5, 134.6, 129.6, 128.2, 124.7, 124.1, 123.2, 119.0, 118.0, 112.6, 112.4 (2C), 111.1, 110.3, 109.9, 107.7, 105.6, 105.4, 103.3, 71.4, 71.2, 71.1, 56.4, 55.5, 55.1, 21.9 (2C), 21.85 (2C), 21.79 (2C). HRMS (ESI) m/z calcd for C\textsubscript{37}H\textsubscript{40}NO\textsubscript{8} (M+H\textsuperscript{+}) : 628.2748; found: 628.2738.

**Lamellarin N:** BCl\textsubscript{3} mediated deisopropylation on 16 (0.025 g, 0.04 mmol) using general procedure 4, afforded lamellarin N as a white solid (0.017 g, 85% yield); \(R_f\) = 0.3 (70% EtOAc + pet. ether) which was spectroscopically found to be in good
agreement with the earlier reported data. IR (neat): 1670, 1588, 1491, 1465, 1256, 1210, 1022, 1012, 955, 860 cm⁻¹; H NMR (400 MHz, DMSO-d₆) δ 9.98 (br s, 1H), 9.88 (br s, 1H), 9.01 (d, J = 7.2 Hz, 1H), 7.25 (d, J = 8.0 Hz, 1H), 7.22 (d, J = 7.6 Hz, 1H), 7.19 (s, 1H), 7.17 (s, 1H), 7.04-7.01 (m, 2H), 6.87 (s, 1H), 6.76 (s, 1H), 3.87 (s, 3H), 3.40 (s, 3H), 3.39 (s, 3H); C NMR (100 MHz, DMSO-d₆): δ 154.4, 148.6, 148.4, 148.0, 147.9, 147.7, 146.4, 144.6, 133.9, 128.8, 127.4, 124.7, 122.1, 118.3, 117.5, 113.7, 112.5, 111.6, 110.6, 108.3, 106.5, 105.7, 105.3, 103.8, 56.2, 55.0, 54.6.

**Gram Scale Synthesis of Ethyl 4-(4-isopropoxy-3-methoxyphenyl)-1-(3-isopropoxy-4-methoxy-phenethyl)-1H-pyrrole-2-carboxylate (17):** As per the general procedure 3, using 5 [ethyl 1-(3-isopropoxy-4-methoxyphenethyl)aziridine-2-carboxylate] (1.33 g, 4.36 mmol, 1 equiv.) and 6c [(Z)-4-(2-bromo-2-nitrovinyl)-1-isopropoxy-2-methoxybenzene] (1.37 g, 4.36 mmol, 1 equiv.) with a reaction time of 5 h, 17 was obtained after flash column chromatography as pale yellow oil (1.85 g, 86% yield); Rf = 0.47; (20% EtOAc + pet. ether). IR (neat): νmax 1696, 1633, 1513, 1470, 1423, 1383, 1249, 1196, 1137, 1092, 1033, 801 cm⁻¹; H NMR (400 MHz, CDCl₃) δ 7.17 (d, J = 2 Hz, 1H), 6.94-6.91 (m, 2H), 6.85 (d, J = 8.8 Hz, 1H), 6.79 (d, J = 2.4 Hz, 1H), 6.78 (d, J = 8.4 Hz, 1H), 6.69 (dd, J₁ = 2 Hz, J₂ = 8 Hz, 1H), 6.59 (d, J = 2 Hz, 1H), 4.53-4.47 (m, 3H), 4.43-4.37 (m, 1H), 4.32 (q, J = 7.2 Hz, 2H), 3.88 (s, 3H), 3.81 (s, 3H), 2.98 (t, J = 6.8 Hz, 2H), 1.39 (t, J=6.8 Hz, 3H), 1.36 (d, J = 6 Hz, 6H), 1.27 (d, J = 6 Hz, 6H); C NMR (100 MHz, CDCl₃): δ 161.1, 150.6, 149.1, 147.2, 145.8, 130.9, 128.2, 125.4, 123.8, 122.1, 121.4, 117.4, 116.8, 116.5, 115.2, 112.0, 109.4, 71.6, 71.5, 60.0, 56.0, 55.97, 51.3, 37.7, 22.1 (2C), 22.0 (2C), 14.5. HRMS (ESI) m/z calcd for C₂₉H₃₈NO₆ (M+H)⁺: 496.2694; found: 496.2689.

**4-(4-isopropoxy-3-methoxyphenyl)-1-(3-isopropoxy-4-methoxyphenethyl)-1H-pyrrole-2-carboxylic acid (18):** Applying the saponification procedure described for
accessing acid 8, hydrolysis of ester 17 (0.55 g, 1.11 mmol, 1 equiv.) in EtOH : H$_2$O (3:1, 15 mL) using crushed NaOH pellets (0.22 g, 5.55 mmol, 5 equiv.) with reaction time of 5 h furnished the pure acid 18 as a white solid (0.46 g, 90% yield); $R_f = 0.5$ (50% EtOAc + pet. ether); mp 114-116°C. IR (neat): $\nu_{\text{max}}$ 1723, 1659, 1564, 1547, 1512, 1478, 1462, 1257, 1235, 1194, 1141, 1112, 1036, 954 cm$^{-1}$; $^1$H NMR (400 MHz, CDCl$_3$) $\delta$ 7.34 (d, $J = 2$ Hz, 1H), 6.95-6.92 (m, 2H), 6.89-6.87 (m, 2H), 6.80 (d, $J = 8.0$ Hz, 1H), 6.69 (dd, $J_1 = 2$ Hz, $J_2 = 8.4$ Hz, 1H), 6.64 (d, $J = 7.2$ Hz, 2H), 1.37 (d, $J = 6$ Hz, 6H), 1.30 (d, $J = 6$ Hz, 6H); $^{13}$C NMR (100 MHz, CDCl$_3$): $\delta$ 165.8, 150.7, 149.2, 147.3, 146.0, 130.8, 127.8, 126.9, 124.4, 121.3, 120.9, 117.4, 117.2, 116.6, 116.5, 112.1, 109.4, 71.7, 71.4, 56.0, 55.9, 51.6, 37.7, 22.14 (2C), 22.11 (2C). HRMS (ESI) m/z calcd for C$_{27}$H$_{34}$NO$_6$ (M+H)$^+$: 468.2381; found: 468.2376.

3-isopropoxy-4-methoxyphenyl 4-(4-isopropoxy-3-methoxyphenyl)-1-(3-isopropoxy-4-methoxyphenethyl)-1H-pyrrole-2-carboxylate (19): Following the general procedure 2, using acid 18 (0.50 g, 1.08 mmol, 1 equiv.) and 9c [3-isopropoxy-4-methoxyphenol] (0.20 g, 1.08 mmol, 1 equiv.), 19 was obtained as a pale yellow oil (0.607 g, 89% yield); $R_f = 0.3$ (20% EtOAc + pet. ether). IR (neat): $\nu_{\text{max}}$1714, 1606, 1512, 1470, 1423, 1384, 1226, 1185, 1137, 1110, 1068, 1048, 987 cm$^{-1}$; $^1$H NMR (400 MHz, DCl$_3$) 7.40 (d, $J = 1.2$ Hz, 1H), 6.98-6.96 (m, 2H), 6.92-6.87 (m, 3H), 6.79-6.73 (m, 3H), 6.69 (dd, $J_1 = 1.6$ Hz, $J_2 = 8.4$ Hz, 1H), 6.61 (d, $J = 2$ Hz, 1H), 4.56-4.49 (m, 4H), 4.42-4.36 (m, 1H), 3.89 (s, 3H), 3.87 (s, 3H), 3.81 (s, 3H), 3.01 (t, $J = 7.2$ Hz, 2H), 1.40 (d, $J = 6$ Hz, 6H), 1.37 (d, $J = 6.4$ Hz, 6H), 1.26 (d, $J = 6$ Hz, 6H); $^{13}$C NMR (100 MHz, CDCl$_3$): $\delta$ 159.6, 150.6, 149.1, 147.9, 147.7, 147.0, 145.9, 144.0, 130.6, 127.7, 126.4, 124.2, 121.5, 121.0, 117.4, 116.8, 116.4, 116.3, 113.5, 112.02, 111.99, 109.7, 109.4, 71.6, 71.4 (2C), 56.3, 55.9 (2C), 51.3, 37.6, 22.1(2C), 22.0 (2C), 21.9 (2C). HRMS (ESI) m/z calcd for C$_{37}$H$_{46}$NO$_8$ (M+H)$^+$: 632.3218; found: 632.3211
**3,11-diisopropoxy-14-(4-isopropoxy-3-methoxyphenyl)-2,12-dimethoxy-8,9-dihydro-6H-chromeno[4',3':4,5]pyrrolo[2,1-a] isoquinolin-6-one (20):** Following the general CDC reaction procedure 3, using 19 (0.47 g, 0.75 mmol), pentacyclic lactone 20 was obtained as a white solid (0.19 g, 40% yield); \( R_f = 0.4 \) (30% EtOAc + pet. ether). IR (neat): \( \nu_{\text{max}} \) 2930, 1700, 1508, 1485, 1419, 1281, 1270, 1253, 1192, 1121, 1030, 1015, 930 cm\(^{-1}\); \(^1\)H NMR (400 MHz, CDCl\(_3\)) \( \delta \) 7.10-7.03 (m, 3H), 6.91 (s, 1H), 6.76 (s, 1H), 6.73 (s, 1H), 6.66 (s, 1H), 4.85-4.72 (m, 2H), 4.63-4.50 (m, 3H), 3.81 (s, 3H), 3.42 (s, 3H), 3.33 (s, 3H), 3.09 (t, \( J = 6.4 \) Hz, 2H), 1.41-1.36 (m, 18H); \(^{13}\)C NMR (100 MHz, CDCl\(_3\)) \( \delta \) 155.7, 151.3, 148.6, 147.3, 147.0, 146.9, 146.5, 146.0, 136.0, 128.6, 128.2, 126.4, 123.4, 120.2, 116.9, 114.9, 114.65, 114.61, 113.7, 110.4, 109.2, 104.9, 103.5, 71.8, 71.45, 71.36, 56.2, 55.5, 55.1, 42.5, 28.6, 22.1 (2C), 21.94, 21.89, 21.83 (2C). HRMS (ESI) m/z calcd for C\(_{37}\)H\(_{42}\)NO\(_8\) (M+H\(^+\)) : 628.2905; found: 628.2894.

**3,11-diisopropoxy-14-(4-isopropoxy-3-methoxyphenyl)-2,12-dimethoxy-6H-chromeno[4',3':4,5]pyrrolo[2,1-a]isoquinolin-6-one (21):** Applying the same oxidation procedure as described for synthesis of 16, oxidation of 20 (0.020 g, 0.03 mmol, 1 equiv.) using DDQ (0.017 g, 0.075 mmol, 2.5 equiv.) afforded 21 as a white solid (0.019 g, 96% yield); \( R_f = 0.5 \) (30% EtOAc + pet. ether). IR (neat): \( \nu_{\text{max}} \) 2924, 1693, 1519, 1480, 1434, 1286, 1229, 1180, 1110, 1039, 945, 859 cm\(^{-1}\); \(^1\)H NMR (400 MHz, CDCl\(_3\)) \( \delta \) 9.22 (d, \( J = 7.2 \) Hz, 1H), 7.18-7.17 (m, 3H), 7.12 (s, 1H), 7.09 (s, 1H), 7.02 (d, \( J = 7.6 \) Hz, 1H), 6.96 (s, 1H), 6.75 (s, 1H), 4.72-4.67 (m, 1H), 4.66-4.61 (m, 1H), 4.60-4.54 (m, 1H), 3.84 (s, 3H), 3.44 (s, 3H), 3.43 (s, 3H), 1.43 (d, \( J = 6 \) Hz, 12H), 1.40 (d, \( J = 6 \) Hz, 6H); \(^{13}\)C NMR (100 MHz, CDCl\(_3\)) \( \delta \) 155.6, 151.4, 150.2, 148.5, 147.9, 147.2, 146.6, 146.5, 134.5, 129.5, 128.8, 124.8, 123.9, 123.2, 119.0, 116.8, 115.0, 112.4, 111.1, 110.4, 110.0, 107.8, 105.7, 105.4, 103.4, 71.8, 71.5, 71.2, 56.2,
55.4, 55.2, 21.9 (3C), 21.88, 21.84, 21.82. HRMS (ESI) m/z calcd for C_{37}H_{40}NO_{8} (M+H)^+ : 628.2748; found: 628.2738.

**Lamellarin D**: BCl₃ mediated deisopropylation on 21 (0.025 g, 0.04 mmol) using general procedure 4, afforded lamellarin D as a white solid (0.020 g, 80% yield); R_f = 0.4 (80% EtOAc + pet. ether) which was spectroscopically found to be in good agreement with the earlier reported data.⁷⁰ IR (neat): 1670, 1598, 1556, 1491, 1499, 1433, 1404, 1359, 1277 cm⁻¹; ¹H NMR (400 MHz, DMSO-d₆) δ 9.90 (br s, 2H), 9.39 (br s, 1H), 9.02 (d, J = 7.6 Hz, 1H), 7.22 (d, J = 7.6 Hz, 1H), 7.21 (s, 1H), 7.17 (d, J = 1.6 Hz, 1H), 7.15 (s, 1H), 7.11 (d, J = 8.0 Hz, 1H), 7.03 (dd, J₁ = 1.6 Hz, J₂ = 8.0 Hz, 1H), 6.88 (s, 1H), 6.73 (s, 1H), 3.79 (s, 3H), 3.39 (s, 6H); ¹³C NMR (100 MHz, DMSO-d₆) δ 154.4, 148.7, 148.5, 148.4, 147.9, 146.8, 146.4, 144.6, 134.1, 129.0, 125.5, 124.7, 123.8, 122.1, 117.6, 116.4, 115.0, 112.4, 111.5, 110.9, 108.4, 106.4, 105.7, 105.4, 103.8, 56.0, 55.1, 54.5. HRMS (ESI) m/z calcd for C_{28}H_{21}NO_{8} (M+H)^+ : 500.1340; found: 500.1335.

**Supporting Information**

¹H and ¹³C spectral copies of the synthesized compounds.

Supporting Information File 1:

File Name: Supporting Information

File Format: PDF

**Acknowledgements**

We are grateful to Dr. Sapna Tripathi Khan for proof reading the manuscript.
Funding

Funding text T. K. gratefully acknowledges the financial support from the Council of Scientific and Industrial Research (CSIR), India (Grant No. 02(0320)/17/EMR-II) as well as Science and Engineering Research Board (SERB), DST, India (Grant No. CRG/2019/002595). V.K is thankful to MHRD for the financial support during his Ph.D. A.S. and D.K. acknowledges the financial support in the form of SRF from DST/CSIR and UGC respectively. All the authors also acknowledge the financial and infrastructural support from IIT Bhubaneswar.

References

1. For reviews, see: (a) Bailly, C. *Mar. Drugs* 2015, 13, 1105-1123. (b) Fukuda, T.; Ishibashi, F.; Iwao, M. *Heterocycles* 2011, 83, 491-529.

2. For reviews covering the synthetic approaches until 2014, see: (a) Imbri, D.; Tauber, J.; Opatz, T. *Mar. Drugs* 2014, 12, 6142-6177. (b) Pla, D.; Albericio, F.; Alvarez, M. *MedChemComm* 2011, 2, 689-697.

3. For the latest reports towards lamellarins, see: (a) Watanabe, T.; Mutoh, Y.; Saito, S. *Org. Biomol. Chem.* 2020, 18, 81-85. (b) Klintworth, R.; de Koning, C. B.; Michael, J. P. *J. Org. Chem.* 2020, 85, 1054-1061. (c) Matveeva, M. D.; Purgatorio, R.; Voskressensky, L. G.; Alomare, C. D. *Future Med. Chem.* 2019, 11, 2735-2755. (d) Shirley, H. J.; Koyioni, M.; Muncan, F.; T. J. Donohoe, *Chem. Sci.*, 2019, 10, 4334-4338. (e) Fukuda, T.; Ishibashi, F.; Iwao, M. The Alkaloids: Chemistry and Biology; (Ed. H.-J. Knölker), 2020 (Vol. 83, Chapter 1).

4. (a) Fan, H.; Peng, J. M.; Hamann, T.; Hu, J.-F. *Chem. Rev.* 2008, 108, 264-287. (b) Bracegirdle, J.; Robertson, L. P.; Hume, P. A.; Page, M. J.; Sharrock, A. V.; Ackerley, D. F.; Carroll, A. R.; Keyzers, R. A. *J. Nat. Prod.* 2019, 82, 2000-2008.
5. For selected synthetic reports on type III lamellarins, see: (a) Ramirez-Rodriguez, A.; Mendez, J. M.; Jimenez, C. C.; Leon, F.; Vazquez, A. Synthesis 2012, 44, 3321-3326. (b) Marfil, M.; Albericio, F.; Alvarez, M. Tetrahedron 2004, 60, 8659-8668. (c) Banwell, M. G.; Flynn, B. L.; Hamel, E.; Hockless, D. C. R. Chem. Commun. 1997, 2, 207-208.

6. (a) Pla, D.; Albericio, F.; Alvarez, M. Anti-Cancer Agents Med. Chem. 2008, 8, 746-760. (b) Cironi, P.; Albericio, F.; Alvarez, M. Prog. Heterocycl. Chem. 2005, 16, 1-26. (c) Bailly, C. Curr. Med. Chem.: Anti-Cancer Agents 2004, 4, 363-378.

7. (a) Dialer, C.; Imbri, D.; Hansen, S. P.; Opatz, T. J. Org. Chem. 2015, 80, 11605-11610. (b) Li, Q.; Jiang, J.; Fan, A.; Cui, Y.; Jia, Y. Org. Lett. 2011, 13, 31-3152. (c) Chiu, H.-C.; Tonks, I. A. Angew. Chem. Int. Ed. 2018, 57, 6090-6094.

8. Kumar, V.; Awasthi, A.; Metya, A.; Khan, T. J. Org. Chem. 2019, 84, 11581-11595.

9. A manuscript on the detail computational approach adopted to rationalize the anomalous regioselectivity is under preparation for publication elsewhere.

10. Kumar, V.; Awasthi, A.; Salam, A.; Khan, T. J. Org. Chem. 2019, 84, 11596-11603.

11. While the present synthetic endeavour was in the manuscript preparation stage, the first total synthesis of lamellarin Z appeared in the literature. However, our approach is noteworthy for its conciseness and elegance with which the natural product is accessed.

12. Morikawa, D.; Morii, K.; Yasuda, Y.; Mori, A.; Okano, K. J. Org. Chem. 2020, 85, 8603.

13. (a) Pintori, D. G.; Greaney, M. F. J. Am. Chem. Soc. 2011, 133, 1209-1211. (b) Ueda, K.; Amaiike, K.; Maceiczyk, R. M.; Itami, K.; Yamaguchi, J. J. Am. Chem. Soc. 2014, 136, 13226-13232.

14. Kuan, K. K. W.; Markwell-Heys, A. W.; Cruickshank, M. C.; Tran, D. P.; Adlington, R. M.; Baldwin, J. E.; George, J. H. Bioorg. Med. Chem. 2019, 27, 2449-24465.
15. Yu, H.; Richardson, T. E.; Donnelly, M.; Nguyen, N.; Jiang, X. PTC WO 2014/209978 A1.

16. Urban, S.; Capon, R. J. Aust. J. Chem. 1996, 49, 711-713.

17. Davis, R. A.; Carroll, A. R.; Pierens, G. K.; Quinn, R. J. J. Nat. Prod. 1999, 62, 419-424.

18. Pla, D.; Marchal, A.; Olsen, C. A.; Albericio, F.; Alvarez, M. J. Org. Chem. 2005, 70, 8231-8234.

19. Lindquist, N.; Fenical, W.; Van Duyne, G. D.; Clardy, J. J. Org. Chem. 1988, 53, 4570-4574.

20. Komatsubara, M.; Umeki, T.; Fukuda, T.; Iwao, T. M. J. Org. Chem. 2014, 79, 529-537.

21. Hasse, K.; Willis, A. C.; Banwell, M. G. Eur. J. Org. Chem. 2011, 88–99.

22. Armarego, D. L. F.; Perrin, D. D. Purification of Laboratory Chemicals, 4th ed.; 1996; Elsevier, pp 110–349.

23. Kimura, S.; Pangkruang, W.; Yokoya, M.; Honda, A.; Puthongking, P.; Suwanborirux, K.; Saito, N. Heterocycles, 2014, 88, 363-375.